MedTrace Logo

Study of Normal Conditions of Use, Dosing, and Safety of Intravenous (IV) Administration of Vernakalant (MK-6621-049)

NCT01370629 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2015

Last updated 2019-12-30

Study results available
· View outcomes & findings →

Summary

This non-interventional prospective study is a post-authorization safety study (PASS) of vernakalant conducted to collect information about normal conditions of use and appropriate dosing, and to quantify possible medically significant risks associated with the use of vernakalant in real-world clinical practice.

Conditions

Interventions

DRUG

Vernakalant

Prescribed at the discretion of the physician in accordance with their usual practice

Sponsors & Collaborators

  • Correvio International Sarl

    lead INDUSTRY

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-08-31
Primary Completion
2018-04-05
Completion
2018-05-08

Countries

  • Austria
  • Denmark
  • Finland
  • Germany
  • Spain
  • Sweden

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01370629 on ClinicalTrials.gov